Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative Colitis
Deborah Hartman(Avaxia Biologics (United States)), Barbara S. Fox(Avaxia Biologics (United States)), Emma Erlich(Avaxia Biologics (United States)), Skaison Kim(Avaxia Biologics (United States)), David M. Keane(Avaxia Biologics (United States)), M. Scott Harris(Altimmune (United States)), Randall Burton(Avaxia Biologics (United States)), Daniel E. Tracey(Abbott (United States)), Kailash C. Bhol(Avaxia Biologics (United States)), Brenda Lemos(Avaxia Biologics (United States)), Rutvij Patel(Avaxia Biologics (United States))
Cited by 33
Related Papers
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
|Pharmacology & Therapeutics|2007|1.6k
Ribosome Profiling Reveals Pervasive Translation Outside of Annotated Protein-Coding Genes
|Cell Reports|2014|678
Identification of Long-Lived Proteins Reveals Exceptional Stability of Essential Cellular Structures
|Cell|2013|603